News
Published Data as of
On October 30, 2026, HHS published a draft policy of enforcement discretion for licensed pharmacies and physicians that compound certain peptides.1 Its Appendix A names BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500.2 HHS says compounded drugs are not FDA-approved. HHS also calls the policy interim and not binding.1 PepBank's records hold publications with findings in people for BPC-157, Epitalon and Semax, and none for KPV, MOTS-c or TB-500.3,4,5,6,7,8
On October 30, 2026, HHS announced a draft Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. The notice appeared in the Federal Register.1 HHS says it does not intend to pursue enforcement action against State-licensed pharmacies, Federal facilities or licensed physicians compounding with Appendix A peptides.1,2
HHS opened a comment period on Docket No. HHS-OASH-2026-0496. It runs until 2 weeks after publication in the Federal Register.1
HHS says compounded drugs are not FDA-approved.1,2 HHS calls the policy interim and says it may be revisited. HHS also says it creates no rights and is not binding.1
The peptides are not yet on the 503A bulks list, which is being developed through rulemaking. FDA's future rulemakings may propose adding some or all of them.1 HHS may revisit the interim policy if a safety signal or product quality issue arises.2
BPC-157 and BPC-157 acetate were in Category 2 from September 2023 until April 22, 2026. HHS says neither the placement nor the removal changed their status under section 503A.2 HHS says the same for TB-500, which was in Category 2 from September 29, 2023, until April 22, 2026.2
In a small trial in people, 10 of 12 women with interstitial cystitis reported complete resolution of symptoms after one BPC-157 treatment.15 In a knee pain study in patients, 11 of 12 who received only intra-articular BPC 157 (91.6%) reported significant improvement.16 In a pilot study in people, intravenous BPC-157 infusions in 2 adults had no measurable effect on the tested heart biomarkers.17
PepBank holds 2 publications with findings in people for Epitalon.4 In patients with degenerative retinal lesions, Epitalon therapy gave a positive clinical effect in 90% of the cases.18
PepBank holds 12 publications with findings in people for Semax.5 In patients with acute hemispheric ischemic stroke, adding Semax to combined intensive therapy increased the regress of general cerebral disorders compared with conventional therapy.19 In patients with motor neuron disease, 1% semax did not influence the course of chronic partial denervation.20
PepBank's records hold no result from a study in people for KPV.6 In mice, oral KPV reduced the incidence of dextran sodium sulfate-induced colitis.21
PepBank's records hold no result from a study in people for MOTS-c. A trial registry lists 1 trial of MOTS-c in people.7 In mice, MOTS-c treatment prevented age-dependent insulin resistance.22
PepBank's records hold no result from a study in people for TB-500. A trial registry lists 1 trial of TB-500 in people.8 In rats with repaired Achilles tendons, TB-500 increased maximum load to failure compared with controls.23
The TB-500 studies in PepBank's records include 6 publications with findings in animals.8 In two horses given TB-500 subcutaneously, N-acetylated LKKTETQ and its metabolite N-acetylated LK were detected in plasma.24
HHS says it does not intend to pursue enforcement action against State-licensed pharmacies, Federal facilities or licensed physicians compounding with Appendix A peptides. BPC-157 is named in Appendix A.2 HHS says enforcement discretion is appropriate for subcutaneous, intramuscular, oral and topical dosage forms of BPC-157 acetate.2 HHS says compounded drugs are not FDA-approved.2
PepBank's regulatory record lists Semax as approved in Russia only, registered as Семакс.9 The Russian registration is a prescription medicine in nasal drops, held by Peptogen. Its listed 1% indication is the acute period of moderate to severe ischemic stroke, as part of combined therapy.9 In the United States, HHS says enforcement discretion is appropriate for intranasal use of semax free base.2
HHS opened a comment period on Docket No. HHS-OASH-2026-0496 on regulations.gov. HHS says it lasts until 2 weeks after the date of publication in the Federal Register.1 HHS announced the draft policy on October 30, 2026.1 HHS calls the policy interim and says it may be revisited.1
PepBank's records hold no result from a study in people for MOTS-c. A trial registry lists 1 trial of MOTS-c in people.7 PepBank holds 75 publications with findings in animals and 53 with laboratory findings in cells or tissue for MOTS-c.7 In mice of 2, 12 and 22 months, MOTS-c significantly enhanced physical performance.25
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated